{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:57:19Z","timestamp":1781672239988,"version":"3.54.5"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate efficacy and safety of tebentafusp in patients with metastatic uveal melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      A systematic search was conducted in five databases (Pubmed, Embase, Web of Science, Scopus, and the Cochrane Library) to find articles that evaluate the effectiveness of tebentafusp in patients with metastatic uveal melanoma, from the establishment of the databases to October 13, 2025. Additionally, clinical trials were searched on\n                      <jats:ext-link>clinicaltrials.gov<\/jats:ext-link>\n                      . Meta-analyses were performed to evaluate the frequencies of progression-free survival (PFS), overall survival (OS), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), disease control rate (DCR), Cytokine release syndrome (CRS) and treatment-related adverse events (trAEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of six studies were initially enrolled, involving 850 participants. Among them, 631 patients with evaluable uveal melanoma who received tebentafusp treatment were ultimately included in this meta-analysis (mean age, 60.56 years; 425 [50%] men). The median OS and PFS were 21.3 months and 3.6 months, respectively. The PR, SD, PD,ORR and DCR were 0.09 [95% confidence interval (CI), 0.05 to 0.14], 0.39 (95% CI, 0.35 to 0.43), 0.79 (95% CI, 0.32 to 0.97), 0.09 (95% CI, 0.06 to 0.13) and 0.27 (95% CI, 0.20 to 0.36), respectively. The any grade cytokine release syndrome rate, grade \u2265 3 cytokine release syndrome rate, any grade trAEs rate and grade \u2265 3 trAEs rate were 0.88 (95% CI, 0.84 to 0.91), 0.02 (95% CI, 0.01 to 0.06), 0.98 (95% CI, 0.75 to 1.00) and 0.41 (95% CI, 0.17 to 0.71), respectively. The most common adverse reactions include pyrexia 0.83 (95% CI, 0.79 to 0.86), nausea 0.58 (95% CI, 0.42 to 0.73), fatigue 0.54 (95% CI, 0.38 to 0.70), pruritus 0.72 (95% CI, 0.65 to 0.78), chills 0.60 (95% CI, 0.47 to 0.71), dry skin 0.43 (95% CI, 0.25 to 0.63), hypotension 0.41 (95% CI, 0.36 to 0.45).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The research results show that tebentafusp exhibits modest but potentially meaningful survival benefit despite low response rates for metastatic uveal melanoma patients. Although adverse events often occur, such as cytokine release syndrome of grade three or above, they are usually manageable and controllable. Given the limitations of this study, it is crucial to conduct further multi-center randomized controlled trials and increase the sample size to further verify our results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO: CRD420251234508. Available from\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251234508<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1826626","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:47:54Z","timestamp":1781671674000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Han","family":"Cai","sequence":"first","affiliation":[{"name":"Ophthalmology Center, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Long","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Health Policy and Management, Chinese Academy of Medical Sciences, Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wei","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Tian","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/107327480401100503","article-title":"Choroidal melanoma: natural history and management options","volume":"11","author":"Bell","year":"2004","journal-title":"Cancer Control."},{"key":"B3","doi-asserted-by":"publisher","first-page":"102143","DOI":"10.1016\/j.suronc.2024.102143","article-title":"Advances in the management of regionally metastatic melanoma","volume":"57","author":"Balsay-Patel","year":"2024","journal-title":"Surg Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/sj.bjc.6600919","article-title":"Absence of braf gene mutations in uveal melanomas in contrast to cutaneous melanomas","volume":"88","author":"Edmunds","year":"2003","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor braf and nras mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41467-019-14256-1","article-title":"Single-cell analysis reveals new evolutionary complexity in uveal melanoma","volume":"11","author":"Durante","year":"2020","journal-title":"Nat Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1755-3768.1983.tb04350.x","article-title":"Malignant melanoma of the choroid and the ciliary body 1956\u20131975 in Halland and Gothenburg","volume":"61","author":"Abrahamsson","year":"1983","journal-title":"Acta Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jcjo.2023.02.003","article-title":"Advances in conjunctival melanoma: clinical features, diagnostic modalities, staging, genetic markers, and management","volume":"59","author":"Zeiger","year":"2024","journal-title":"Can J Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1167\/iovs.15-16532","article-title":"Nationwide incidence of ocular melanoma in south korea by using the national cancer registry database (1999\u20132011)","volume":"56","author":"Park","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ijc.20690","article-title":"International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification","volume":"114","author":"Stang","year":"2005","journal-title":"Int J Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102599","DOI":"10.1016\/j.ctrv.2023.102599","article-title":"Uveal melanoma: in the era of new treatments","volume":"119","author":"Wespiser","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal melanoma: 5-year update on incidence, treatment, and survival (Seer 1973\u20132013)","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocular oncology and pathology."},{"key":"B16","unstructured":"American Cancer Society | Cancer Facts & Statistics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101041","DOI":"10.1016\/j.preteyeres.2022.101041","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog Retin Eye Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.biochi.2023.04.013","article-title":"An update on inflammation in uveal melanoma","volume":"212","author":"Liau","year":"2023","journal-title":"Biochimie."},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/CMR.0000000000000468","article-title":"Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: the princess margaret cancer centre experience","volume":"28","author":"Nicholas","year":"2018","journal-title":"Melanoma Res."},{"key":"B21","unstructured":"Eye Cancer Survival Rates."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (Irci) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"103652","DOI":"10.1016\/j.critrevonc.2022.103652","article-title":"The long-term prognosis of patients with untreated primary uveal melanoma: a systematic review and meta-analysis","volume":"172","author":"St\u00e5lhammar","year":"2022","journal-title":"Crit Rev Oncol Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0161-6420(03)00661-4","article-title":"Iodine brachytherapy as an alternative to enucleation for large uveal melanomas","volume":"110","author":"Puusaari","year":"2003","journal-title":"Ophthalmology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijrobp.2006.01.020","article-title":"Proton Beam radiotherapy for uveal melanoma: results of curie institut-orsay proton therapy center (Icpo)","volume":"65","author":"Dendale","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000367715","article-title":"Adjuvant therapy of uveal melanoma: current status","volume":"1","author":"Triozzi","year":"2014","journal-title":"Ocular Oncol Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/bjophthalmol-2021-319700","article-title":"Incidence and mortality of uveal melanoma in Australia (1982\u20132014)","volume":"107","author":"Beasley","year":"2023","journal-title":"Br J Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1758834018757175","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with Pd-1 and Pd-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase Ii study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1167\/iovs.07-0786","article-title":"Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma","volume":"49","author":"Maat","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.3390\/ijms22052669","article-title":"Additive role of immune system infiltration and angiogenesis in uveal melanoma progression","volume":"22","author":"Garc\u00eda-Mulero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1854519","DOI":"10.1080\/2162402X.2020.1854519","article-title":"Presence of tumor-infiltrating Cd8(+) T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis","volume":"9","author":"Johansson","year":"2020","journal-title":"Oncoimmunology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"673838","DOI":"10.3389\/fcell.2021.673838","article-title":"Construction of a promising tumor-infiltrating Cd8+ T cells gene signature to improve prediction of the prognosis and immune response of uveal melanoma","volume":"9","author":"Sun","year":"2021","journal-title":"Front Cell Devel Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"108069","DOI":"10.1016\/j.exer.2020.108069","article-title":"The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma","volume":"196","author":"Wang","year":"2020","journal-title":"Exp Eye Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/imt-2017-0066","article-title":"Pd-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma","volume":"9","author":"Javed","year":"2017","journal-title":"Immunotherapy."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase Iii, multicenter, randomized trial (Sumit)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/TACG.S69210","article-title":"The genetics of uveal melanoma: current insights","volume":"9","author":"Helgadottir","year":"2016","journal-title":"Appl Clin Genet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1167\/iovs.02-1329","article-title":"Lack of braf mutation in primary uveal melanoma","volume":"44","author":"Cohen","year":"2003","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B42","first-page":"5761","article-title":"3rd, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, et al. Absence of braf and nras mutations in uveal melanoma","volume":"63","author":"Cruz","year":"2003","journal-title":"Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by immtac (Imcgp100) redirected Cd8(+) and Cd4(+) T cells","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology."},{"key":"B44","unstructured":"Fda Approves Tebentafusp-Tebn for Unresectable or Metastatic Uveal Melanoma\n          \n          2022"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2217\/fon-2021-1260","article-title":"Tebentafusp for the treatment of metastatic uveal melanoma","volume":"18","author":"Schank","year":"2022","journal-title":"Future Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.31557\/APJCP.2025.26.7.2267","article-title":"Efficacy and safety of tebentafusp in uveal melanoma: a systematic review and single-arm meta-analysis","volume":"26","author":"AlBarakat","year":"2025","journal-title":"Asian Pac J Cancer Prev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2374647","DOI":"10.1080\/21645515.2024.2374647","article-title":"Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis","volume":"20","author":"Dian","year":"2024","journal-title":"Hum Vaccin Immunother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (Minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg."},{"key":"B51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"Ipdfromkm: reconstruct individual patient data from published kaplan-meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e009028","DOI":"10.1136\/jitc-2024-009028","article-title":"Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma","volume":"12","author":"Sacco","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a Tcr\/Anti-Cd3 bispecific fusion protein targeting Gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med."},{"key":"B57","unstructured":"Kimmtrak (Tebentafusp-Tebn) Injection, for Intravenous Use: Highlights of Prescribing Information\n          \n          2022"},{"key":"B58","doi-asserted-by":"publisher","first-page":"112986","DOI":"10.1016\/j.ejca.2023.112986","article-title":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","volume":"191","author":"Hassel","year":"2023","journal-title":"Eur J Cancer."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/cancers12092557","article-title":"Treatment of metastatic uveal melanoma: systematic review","volume":"12","author":"Rodriguez-Vidal","year":"2020","journal-title":"Cancers"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1826626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:48:04Z","timestamp":1781671684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1826626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":59,"alternative-id":["10.3389\/fmed.2026.1826626"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1826626","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1826626"}}